NB-360 是一种有效的，脑穿透性，口服可生物利用性的双重 BACE1/BACE2 抑制剂 (IC50: 小鼠和人的 BACE1=5 nM; BACE2=6 nM)。NB-360 在转基因淀粉样前体蛋白 (APP) 小鼠中显示出优异的药理学特征，并且强烈减少淀粉样β-淀粉样蛋白和神经炎症。NB-360 可以完全阻断 APP 转基因小鼠脑内 Aβ 沉积的进程。NB-360 与相关的天冬氨酰蛋白酶胃蛋白酶，组织蛋白酶 D 和组织蛋白酶 E 相比具有优异的选择性。
| Cas No. | 1262857-73-7 |
| 分子式 | C21H19F4N5O2 |
| 分子量 | 449.4 |
| 溶解度 | DMSO : 250 mg/mL (556.30 mM; Need ultrasonic) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | IC50: 5 nM (Mouse and human BACE1), 6 nM (BACE2)[1] NB-360 is a potent, brain penetrable, and orally bioavailable dualBACE1/BACE2inhibitor (IC50: mouse and human BACE1=5 nM; BACE2=6 nM). NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in amyloid precursor protein(APP) transgenic mice. NB-360 can completely block the progression of Aβ deposition in the brains of APP transgenic mice. NB-360 shows excellent selectivity over the related aspartyl proteases pepsin, cathepsin D and cathepsin E[1][2]. |
